David Sawyer, MD
Cardiovascular Disease · Wilmington, NCNPI 1710971577
Payments from drug & device makers
Across 15 payments — averaging $17.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$210
- E.r. Squibb & Sons, L.L.C.$19
- Masimo Corporation$17
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$13
What the payments were for
- Food & beverage$258100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 12 | $210 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Masimo Corporation | 1 | $17 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $13 |
How this compares
$258 in reported general payments places this provider in the 15th percentile of 727 cardiovascular disease providers in North Carolina.
See all cardiovascular disease providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 366 | $454,693 |
| XareltoRivaroxaban | 108 | $163,925 |
| Repatha SureclickEvolocumab | 113 | $155,688 |
| EntrestoSacubitril/Valsartan | 43 | $42,339 |
| Praluent PenAlirocumab | 37 | $39,218 |
| FarxigaDapagliflozin Propanediol | 33 | $25,008 |
| Metoprolol Succinate | 1,319 | $19,025 |
| JardianceEmpagliflozin | 11 | $18,904 |
| BrilintaTicagrelor | 32 | $18,045 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 309 | $7,939 |
| Ezetimibe | 264 | $6,453 |
| Atorvastatin Calcium | 554 | $6,068 |
| Rosuvastatin Calcium | 353 | $5,638 |
| Flecainide Acetate | 118 | $5,466 |
| Dofetilide | 24 | $5,165 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Wilmington
- Matthew JanikWilmington$4M
- John AlexanderDurham$76.8M
- Christopher GrangerDurham$24.7M
- Jonathan PicciniDurham$14.3M
- Adrian HernandezDurham$13.2M
- Gary FelkerDurham$12.7M
- Robert MentzDurham$6M
- Michael ShapiroWinston-Salem$5.4M
- Kirkwood AdamsChapel Hill$4.9M
- Nishant ShahDurham$3.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.